Suggested remit: To appraise the clinical and cost effectiveness of danicopan with a C5 inhibitor within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria with extravascular haemolysis.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
5088
|
Provisional Schedule
| Committee meeting |
07 May 2024 |
| Expected publication |
17 July 2024 |
Project Team
| Project lead |
Celia Mayers |
Email enquiries
| External Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors |
Alexion Pharmaceuticals (danicopan) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
PNH Support |
| Professional groups |
National PNH Service |
| |
Royal College of Physicians |
| Comparator companies |
Alexion Pharmaceuticals (eculizumab, ravulizumab) |
| |
Novartis Pharmaceuticals (Iptacopan) – confidentiality agreement not signed, not participating |
| |
Swedish Orphan Biovitrum (pegcetacoplan) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
National Institute for Health Research |
|
Date
|
Update
|
|
26 September 2023
|
Invitation to participate |
|
22 March 2023 - 21 April 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5088 |
|
22 March 2023
|
In progress. Scoping commencing |
|
14 March 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual